-
chevron_right
Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
news.movim.eu / ArsTechnica • 15 January
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price negotiations that were put in place by the Biden administration's Inflation Reduction Act (IRA).
"They need to fix [the IRA]," Eli Lilly CEO Dave Ricks told Bloomberg at the JPMorgan Healthcare Conference in San Francisco.
The results of the first round of IRA negotiations , announced in August, saw the list prices of 10 high-cost drugs get slashed by as much as 79 percent. Collectively, the negotiated prices are estimated to save seniors $1.5 billion in out-of-pocket costs in 2026, when the prices go into effect. The savings will likely be well received, given that KFF polling has found that over a quarter of Americans struggle to afford prescription medications , and 31 percent say they haven't taken medicines as prescribed due to costs.